Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ISHL HL Update 2021 | Less aggressive approaches in relapsed/refractory Hodgkin lymphoma

Alison Moskowitz • 19 Mar 2021
ISHL HL Update 2021
Hodgkin Lymphoma Lymphoma Antibodies Pembrolizumab

Alison Moskowitz, MD, Memorial Sloan Kettering Cancer Center, New York City, NY, highlights areas of unmet need for patients with relapsed/refractory Hodgkin lymphoma (HL), including personalized, less aggressive approaches in the second-line setting, and potentially removing transplantation from the treatment approach for favorable patients with Hodgkin lymphoma. This interview took place at the Update on Hodgkin Lymphoma 2021, a Virtual ISHL event.

More from Alison Moskowitz

5:01
Relapsed & refractory classic Hodgkin lymphoma
Alison Moskowitz • 19 Mar 2021
1:40
Personalized approaches to Hodgkin lymphoma
Alison Moskowitz • 19 Mar 2021
2:36
Angioimmunoblastic T-cell lymphoma treatment
Alison Moskowitz • 2 Jun 2019
1:17
Changes in second-line lymphoma treatment
Alison Moskowitz • 2 Jun 2019

Related Videos

1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
2:28
Checkpoint inhibitors vs brentuximab vedotin as salvage therapy prior to alloSCT for HL
Jacopo Mariotti • 15 Apr 2024
1:37
Exciting CAR-T clinical trials in LBCL and FL
Gloria Iacoboni • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals